insights

COVID-19 Vaccine Updates and Latest Information

Since the beginning of 2021, The Institute for Functional Medicine has presented a series of updates for practitioners about the latest medical research on mitigating SARS-CoV-2 infection and addressing post-acute sequelae of SARS-CoV-2 (PASC). These feature members of IFM’s COVID-19 task force and guest subject matter experts addressing the latest updates and answering audience questions. The recordings of all of these updates are available below.

IFM has also released a free online resource called Key Clinical Takeaways for Mitigating SARS-CoV-2 Infection. This online learning module discusses viral mechanisms of SARS-CoV-2 infection and offers key clinical considerations and therapeutic interventions to patients at various clinical stages of infection, including pre-exposure, post-exposure without symptoms, and post-exposure with symptoms. It details the specific interventions that you can put into practice right now at this stage of the pandemic to mitigate this risk for all of your patients. Vaccines are helpful in decreasing the severity of illness and the recommendations are helpful for both vaccinated and unvaccinated patients.

Key Clinical Takeaways for Mitigating SARS-CoV-2 Infection

MAY 2022

MAY TRANSCRIPT

Show Previous Updates +

Vaccine Information

As discussed by the panelists, in order to properly assess each vaccine, IFM has created this informational dashboard for each approved vaccine, as well as those in phase 3 clinical trials. This dashboard was last updated February 7, 2022 and IFM will not be updating it further. Due to the evolving nature of the SARS-CoV-2 pandemic, new information may be available that is not represented here but this resource will continue to be available as is for reference.

Click on table to zoom

Current Data On Vaccine Efficacy Against Omicron

Current Data On Prior Infection Efficacy Against Omicron

Historical Data From Pre-Omicron

References

  1. US Food and Drug Administration. Comirnaty and Pfizer-BioNTech COVID-19 vaccine. Revised October 29, 2021. Accessed November 5, 2021. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-va­ccine
  2. Centers for Disease Control and Prevention. CDC recommends pediatric COVID-19 vaccine for children 5 to 11 years. Published November 2, 2021. Accessed November 5, 2021. https://www.cdc.gov/media/releases/2021/s1102-PediatricCOVID-19Vaccine.html
  3. Pfizer. An additional dose of the vaccine is authorized for persons who meet the guidelines below. Accessed February 6, 2022. https://www.comirnaty.com/booster-dose/
  4. Centers for Disease Control and Prevention. COVID-19 vaccinations in the United States. Updated February 10, 2022. Accessed February 10, 2022. https://covid.cdc.gov/covid-data-tracker/#vaccinations
  5. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
  6. Jenco M. AAP, CDC recommend COVID-19 vaccine for ages 12 and older. AAP News and Journals. Published May 12, 2021. Accessed May 13, 2021. https://www.aappublications.org/news/2021/05/12/cdc-aap-pfizer-covid-vaccine-teens-051221
  7. Perez JL. COVID-19 vaccine BNT162b2: safety, immunogenicity, and efficacy in subjects 12-15 years-old. Centers for Disease Control and Prevention. Published May 12, 2021. Accessed May 13, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-05-12/02-COVID-Perez-508.pdf
  8. Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. Published online December 14, 2021. doi:10.1038/s41591-021-01630-0
  9. US Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine frequently asked questions. Published November 19, 2021. Accessed February 6, 2022. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine-frequently-asked-questions
  10. US Food and Drug Administration. Spikevax and Moderna COVID-19 vaccine. Published February 8, 2021. Accessed February 6, 2022. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/spikevax-and-moderna-covid-19-vaccine
  11. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA takes additional actions on the use of a booster dose for COVID-19 vaccines. Published October 20, 2021. Accessed November 5, 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-additional-actions-use-booster-dose-covid-19-vaccines
  12. US Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers): emergency use authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Revised January 31, 2022. Accessed February 6, 2022. https://www.fda.gov/media/144637/download
  13. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
  14. US Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee meeting February 26, 2021: FDA briefing document Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. Revised February 26, 2021. Accessed February 28, 2021. https://www.fda.gov/media/146217/download
  15. US Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers): emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Revised January 31, 2022. Accessed February 6, 2022. https://www.fda.gov/media/146304/download
  16. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med. 2021;384(23):2187-2201. doi:10.1056/NEJMoa2101544
  17. Katella K. J&J vaccine and Guillain-Barré syndrome: information on the FDA warning. Yale Medicine. Published December 17, 2021. Accessed February 6, 2022. https://www.yalemedicine.org/news/covid-vaccine-guillain-barre-syndrome
  18. Medicines & Healthcare Products Regulatory Agency. Decision: summary of product characteristics for Vaxzevria. Updated October 21, 2021. Accessed November 5, 2021. https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/information-for-healthcare-professionals-on-covid-19-vaccine-astrazeneca
  19. European Medicines Agency. EMA recommends COVID-19 vaccine AstraZeneca for authorisation in the EU. Updated January 29, 2021. Accessed March 12, 2021. https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu#:~:text=COVID%2D19%20Vaccine%20AstraZeneca%20is,Commission%20on%2029%20January%202021.&text=This%20is%20the%20third%20COVID,EMA%20has%20recommended%20for%20authorisation
  20. NHS. Booster dose of the coronavirus (COVID-19) vaccine. Reviewed February 10, 2022. Accessed February 6, 2022. https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-booster-vaccine/
  21. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK [published correction appears in Lancet. 2021; 397(10269):98]. Lancet. 2021;397(10269):99-111. doi:10.1016/S0140-6736(20)32661-1
  22. Bussel JB, Connors JM, Cines DB, et al. Vaccine-induced immune thrombotic thrombocytopenia. American Society of Hematology. Updated January 28, 2022. Accessed February 6, 2022. https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia
  23. Novavax. World Health Organization grants second emergency use listing for Novavax COVID-19 vaccine. Published December 20, 2021. Accessed February 6, 2022. https://ir.novavax.com/2021-12-20-World-Health-Organization-Grants-Second-Emergency-Use-Listing-for-Novavax-COVID-19-Vaccine
  24. Novavax. Novavax submits request to the U.S. FDA for emergency use authorization of COVID-19 vaccine. Published January 31, 2021. Accessed February 6, 2022. https://ir.novavax.com/2022-01-31-Novavax-Submits-Request-to-the-U-S-FDA-for-Emergency-Use-Authorization-of-COVID-19-Vaccine
  25. Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2022;386(6):531-543. doi:10.1056/NEJMoa2116185
  26. Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 COVID-19 vaccine. N Engl J Med. 2021;385(13):1172-1183. doi:10.1056/NEJMoa2107659
  27. Cameroni E, Bowen JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. Published online December 23, 2021. doi:10.1038/s41586-021-04386-2 https://www.ahri.org/omicron-incompletely-escapes-immunity-induced-by-the-pfizer-vaccine/
  28. Africa Health Research Institute. Omicron incompletely escapes immunity induced by the Pfizer vaccine. Published December 7, 2021. Accessed February 6, 2022. https://www.ahri.org/omicron-incompletely-escapes-immunity-induced-by-the-pfizer-vaccine/
  29. Wilhelm A, Widera M, Grikscheit K, et al. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies. medRxiv. [Preprint]. Published December 13, 2021. Accessed February 6, 2022. doi:10.1101/2021.12.07.21267432
  30. Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N Engl J Med. 2022;386(5):492-494. doi:10.1056/NEJMc2119358
  31. Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;185(3):457-466.e4. doi:10.1016/j.cell.2021.12.033
  32. Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N Engl J Med. 2022;386(5):492-494. doi:10.1056/NEJMc2119358
  33. Discovery Health. Discovery Health, South Africa’s largest private health insurance administrator, releases at-scale, real-world analysis of Omicron outbreak based on 211 000 COVID-19 test results in South Africa, including collaboration with the South Africa. Published December 14, 2021. Accessed February 6, 2022. https://discovery-holdings-ltd.mynewsdesk.com/pressreleases/discovery-health-south-africas-largest-private-health-insurance-administrator-releases-at-scale-real-world-analysis-of-omicron-outbreak-based-dot-dot-dot-3150697.pdf
  34. Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. medRxiv. [Preprint]. Published December 14, 2021. Accessed February 6, 2022. doi:10.1101/2021.12.14.21267615
  35. Ferguson N, Ghani A, Cori A, Hogan A, Hinsley W, Volz E. Report 49 – growth, population distribution and immune escape of Omicron in England. Imperial College London. Published December 16, 2021. Accessed February 6, 2022. https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-49-Omicron/
  36. Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. medRxiv. [Preprint]. Published December 14, 2021. Accessed February 6, 2022. doi:10.1101/2021.12.14.21267615
  37. UK Health Security Agency. Boosters continue to provide high levels of protection against severe disease from Omicron in older adults. UK Health Security Agency. Published January 7, 2022. Accessed February 6, 2022. https://www.gov.uk/government/news/boosters-continue-to-provide-high-levels-of-protection-against-severe-disease-from-omicron-in-older-adults
  38. Sheikh A, Kerr S, Woolhouse M, McMenamin J, Robertson C. Severity of Omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland. The University of Edinburgh. Published December 22, 2021. Accessed February 6, 2022. https://www.research.ed.ac.uk/en/publications/severity-of-omicron-variant-of-concern-and-vaccine-effectiveness-
  39. Bar-On YM, Goldberg Y, Mandel M, et al. Protection against COVID-19 by BNT162b2 booster across age groups. N Engl J Med. 2021;385(26):2421-2430. doi:10.1056/NEJMoa2115926
  40. Bar-On YM, Goldberg Y, Mandel M, et al. Protection by 4th dose of BNT162b2 against Omicron in Israel. medRxiv. [Preprint]. Published February 1, 2022. Accessed February 6, 2022. doi:10.1101/2022.02.01.22270232
  41. Redd AD. CD8+ T cell responses and SARS-CoV-2 variants. National Institute of Allergy and Infectious Diseases. Accessed February 6, 2022. https://cdn.who.int/media/docs/default-source/blue-print/andy-reddy_c19_whoconsulation_15dec2021.pdf?sfvrsn=1ae61e5_7
  42. Pfizer. Pfizer and BioNTech provide update on Omicron variant. Published December 8, 2021. Accessed February 6, 2022. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-omicron-variant
  43. Keeton R, Tincho MB, Ngomti A, et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature. Published online January 31, 2022. doi:10.1038/s41586-022-04460-3
  44. Doria-Rose NA, Shen X, Schmidt SD, et al. Booster of mRNA-1273 strengthens SARS-CoV-2 Omicron neutralization. medRxiv. [Preprint]. Published December 20, 2021. Accessed February 6, 2022. doi:10.1101/2021.12.15.21267805
  45. Doria-Rose NA, Shen X, Schmidt SD, et al. Booster of mRNA-1273 strengthens SARS-CoV-2 Omicron neutralization. medRxiv. [Preprint]. Published December 20, 2021. Accessed February 6, 2022. doi:10.1101/2021.12.15.21267805
  46. Moderna. Moderna announces preliminary booster data and updates strategy to address Omicron variant. Published December 20, 2021. Accessed February 6, 2022. https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-Preliminary-Booster-Data-and-Updates-Strategy-to-Address-Omicron-Variant/default.aspx
  47. Wilhelm A, Widera M, Grikscheit K, et al. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies. medRxiv. [Preprint]. Published December 13, 2021. Accessed February 6, 2022. doi:10.1101/2021.12.07.21267432
  48. Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance – VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):139-145. doi:10.15585/mmwr.mm7104e3
  49. Atmar RL, Lyke KE, Deming ME, et al. Homologous and heterologous COVID-19 booster vaccinations. N Engl J Med. Published online January 26, 2022. doi:10.1056/NEJMoa2116414
  50. Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467-484.e15. doi:10.1016/j.cell.2021.12.046
  51. Head E, van Elsland SL. Omicron largely evades immunity from past infection or two vaccine doses. Imperial College London. Published December 17, 2021. Accessed February 6, 2022. https://www.imperial.ac.uk/news/232698/omicron-largely-evades-immunity-from-past/amp/
  52. Novavax. Novavax announces initial Omicron cross-reactivity data from COVID-19 vaccine booster and adolescent studies. Published December 22, 2021. Accessed February 6, 2022. https://ir.novavax.com/2021-12-22-Novavax-Announces-Initial-Omicron-Cross-Reactivity-Data-from-COVID-19-Vaccine-Booster-and-Adolescent-Studies
  53. Dolzhikova IV, Iliukhina AA, Kovyrshina AV, et al. Sputnik light booster after Sputnik V vaccination induces robust neutralizing antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant. medRxiv. [Preprint]. Published December 21, 2021. Accessed February 6, 2022. https://www.medrxiv.org/content/10.1101/2021.12.17.21267976v1
  54. Costa Clemens SA, Weckx L, Clemens R, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022;399(10324):521-529. doi:10.1016/s0140-6736(22)00094-0
  55. Cameroni E, Bowen JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. Published online December 23, 2021. doi:10.1038/s41586-021-04386-2
  56. Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization Nature. Published online December 23, 2021. doi:10.1038/s41586-021-04389-z
  57. Ferguson N, Ghani A, Cori A, Hogan A, Hinsley W, Volz E. Report 49 – growth, population distribution and immune escape of Omicron in England. Imperial College London. Published December 16, 2021. Accessed February 6, 2022. https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-49-Omicron/
  58. Zou J, Xia H, Xie X, et al. Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection. Nat Commun. 2022;13(1):852. doi:10.1038/s41467-022-28544-w
  59. Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N Engl J Med. 2022;386(5):494-496. doi:10.1056/NEJMc2119270
  60. León TM, Dorabawila V, Nelson L, et al. COVID-19 cases and hospitalizations by COVID-19 vaccination status and previous COVID-19 diagnosis – California and New York, May-November 2021. MMWR Morb Mortal Wkly Rep. 2022;71(4):125-131. doi:10.15585/mmwr.mm7104e1
  61. Miyamoto S, Arashiro T, Adachi Y, et al. Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants. medRxiv. [Preprint]. Published January 1, 2022. Accessed February 6, 2022. https://www.medrxiv.org/content/10.1101/2021.12.28.21268481v1
  62. World Health Organization. Tracking SARS-CoV-2 variants. Updated November 26, 2021. Accessed December 6, 2021. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
  63. Mahase E. COVID-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper shows. BMJ. 2020;371:m4826. doi:10.1136/bmj.m4826
  64. Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397(10277):875-877. doi:10.1016/S0140-6736(21)00448-7
  65. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819-1829. doi:10.1016/S0140-6736(21)00947-8
  66. Levine-Tiefenbrun M, Yelin I, Katz R, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021;27(5):790-792. doi:10.1038/s41591-021-01316-7
  67. Mizrahi B, Lotan R, Kalkstein N, et al. Correlation of SARS-CoV-2 breakthrough infections to time-from-vaccine. Nat Commun. 2021;12(1):6379. doi:10.1038/s41467-021-26672-3
  68. Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. Published online October 27, 2021. doi:10.1056/NEJMoa2114228
  69. Nanduri S, Pilishvili T, Derado G, et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant – National Healthcare Safety Network, March 1 – August 1, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1163-1166. doi:10.15585/mmwr.mm7034e3
  70. Rosenberg ES, Holtgrave DR, Dorabawila V, et al. New COVID-19 cases and hospitalizations among adults, by vaccination status – New York, May 3-July 25, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1150-1155. doi:10.15585/mmwr.mm7034e1
  71. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. Published online September 1, 2021. doi:10.1016/S1473-3099(21)00460-6
  72. Oliver S. EtR framework: Pfizer-BioNTech COVID-19 vaccine in children aged 5-11 years. Centers for Disease Control and Prevention. Updated November 4, 2021. Accessed November 5, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-11-2-3/08-COVID-Oliver-508.pdf
  73. Pfizer. Pfizer and BioNTech confirm high efficacy and no serious safety concerns through up to six months following second dose in updated topline analysis of landmark COVID-19 vaccine study. Published April 1, 2021, Accessed April 15, 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious
  74. Centers for Disease Control and Prevention. Science brief: COVID-19 vaccines and vaccination. Updated September 15, 2021. Accessed November 5, 2021. https://www.cdc.gov/coronavirus/2019-ncov/more/fully-vaccinated-people.html#ref29
  75. Parry HM, Tut G, Faustini S, et al. BNT162b2 vaccination in people over 80 years of age induces strong humoral immune responses with cross neutralization of P.1 Brazilian variant. Updated March 31, 2021. Accessed April 15, 2021. doi:10.2139/ssrn.3816840
  76. Liu Y, Liu J, Xia H, et al. BNT162b2-elicited neutralization against new SARS-CoV-2 spike variants. N Engl J Med. 2021;385(5)472-474. doi:10.1056/NEJMc2106083
  77. Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021;596(7871):273-275. doi:10.1038/s41586-021-03693-y
  78. Centers for Disease Control and Prevention. Delta variant: what we know about the science. Updated August 26, 2021. Accessed Sept 8, 2021. https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html
  79. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585-594. doi:10.1056/NEJMoa2108891
  80. Keehner J, Horton LE, Binkin NJ, et al. Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce. N Engl J Med. 2021;385(14):1330-1332. doi:10.1056/NEJMc2112981
  81. Pouwels KB, Pritchard E, Matthews PC, et al. Effect of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. Published online October 14, 2021. doi:10.1038/s41591-021-01548-710.1038/s41591-021-01548-7
  82. Andrews N, Tessier E, Stowe J, et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. Preprint. medRxiv. Published October 6, 2021. doi:10.1101/2021.09.15.21263583
  83. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N Engl J Med. 2021;385:1393-1400. doi:10.1056/NEJMoa2114255
  84. Falsey AR, Frenck RW, Walsh EE, et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med. 2021;385:1627-1629. doi:10.1056/NEJMc2113468
  85. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093-2100. doi:10.1016/S0140-6736(21)02249-2
  86. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial [published online December 2, 2021]. Lancet. doi:10.1016/S0140-6736(21)02717-3
  87. Centers for Disease Control and Prevention. The Vaccine Adverse Reporting System (VAERS) results. Accessed February 12, 2021. https://wonder.cdc.gov/vaers.html
  88. CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):46-51. doi.10.15585/mmwr.mm7002e1
  89. Tamaki A, Cabrera CI, Li S, et al. Incidence of Bell palsy in patients with COVID-19. JAMA Otolaryngol Head Neck Surg. 2021;147(8):767-768. doi:10.1001/jamaoto.2021.1266
  90. Vogel G, Couzin-Frankel J. Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. Science. Published June 1, 2021. Accessed September 8, 2021. https://www.science.org/news/2021/06/israel-reports-link-between-rare-cases-heart-inflammation-and-covid-19-vaccination
  91. Thompson MG, Burgess JL, Naleway Al, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV2 infection among health care personnel, first responders, and other essential and frontline workers – eight U.S. locations, December 2020 – March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(13):495-500. doi:10.15585/mmwr.mm7013e3
  92. Wu K, Werner AP, Koch M, et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N Engl J Med. 2021;384(15):1468-1470. doi:10.1056/NEJMc2102179
  93. CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine — United States, December 21, 2020–January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(4):125-129. doi:10.15585/mmwr.mm7004e1
  94. Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine. N Engl J Med. 2021;384(19):1824-1835. doi:10.1056/NEJMoa2034201
  95. Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med. 2021;384(20):1964-1965. doi:10.1056/NEJMc2105869
  96. American Society of Hematology. Thrombosis with thrombocytopenia syndrome (also termed vaccine-induced thrombotic thrombocytopenia). Updated August 12, 2021. Accessed September 9, 2021. https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia
  97. Shimabukuro T; CDC COVID-19 Vaccine Task Force. Update: thrombosis with thrombocytopenia syndrome (TTS) following COVID-19 vaccination. Advisory committee on immunization practices (ACIP). Centers for Disease Control and Prevention. Published May 12, 2021. Accessed May 13, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-05-12/07-COVID-Shimabukuro-508.pdf
  98. Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881-891. doi:10.1016/S0140-6736(21)00432-3
  99. Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72-74. doi:10.1016/S0140-6736(20)32623-4
  100.  Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092-2101. doi:10.1056/NEJMoa2104840
  101. European Medicines Agency. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. Updated April 7, 2021. Accessed April 15, 2021. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood
  102. Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 COVID-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1899-1909. doi:10.1056/NEJMoa2103055